We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-18.54%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.69B
AUM Growth
-$959M
Cap. Flow
-$362M
Cap. Flow %
-21.45%
Top 10 Hldgs %
79.99%
Holding
63
New
4
Increased
11
Reduced
6
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$55M
2
ZYME icon
Zymeworks
ZYME
+$30.4M
3
AKRO
Akero Therapeutics
AKRO
+$18.7M
4
BEAM icon
Beam Therapeutics
BEAM
+$13.8M
5
QURE icon
uniQure
QURE
+$8.26M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$129M
2
SWTX
SpringWorks Therapeutics
SWTX
+$56.4M
3
THRD
Third Harmonic Bio
THRD
+$32.7M
4
NMRA icon
Neumora Therapeutics
NMRA
+$22M
5
CRGX
CARGO Therapeutics
CRGX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
26
Replimune Group
REPL
$449M
$8.29M 0.49%
850,341
– –
BCYC
27
Bicycle Therapeutics
BCYC
$275M
$7.73M 0.46%
910,000
– –
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$6.84M 0.41%
862,068
– –
VERV
29
DELISTED
Verve Therapeutics
VERV
$5.71M 0.34%
1,250,000
– –
ADAP
30
DELISTED
Adaptimmune Therapeutics
ADAP
$5.4M 0.32%
27,404,070
– –
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$3.89M 0.23%
155,006
– –
WHWK
32
Whitehawk Therapeutics
WHWK
$182M
$3.71M 0.22%
2,082,000
+1,736,747
+503% +$4.54M
ATRA icon
33
Atara Biotherapeutics
ATRA
$70.4M
$3.4M 0.2%
573,183
+41,049
+8% +$358K
SLDB icon
34
Solid Biosciences
SLDB
$785M
$2.75M 0.16%
+744,450
New +$3.19M
KROS icon
35
Keros Therapeutics
KROS
$199M
$1.91M 0.11%
187,500
– –
NUVB.WS
36
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.7M 0.1%
963,333
– –
RLAY icon
37
Relay Therapeutics
RLAY
$3.99B
$1.68M 0.1%
641,426
– –
KLRS
38
Kalaris Therapeutics
KLRS
$79.5M
$1.62M 0.1%
201,718
+183,949
+1,035% +$1.8M
QURE icon
39
CALL
uniQure
QURE
$2.52B
$1.43M 0.08%
135,000
-250,000
-65% -$3.51M
PRME icon
40
Prime Medicine
PRME
$558M
$1.39M 0.08%
700,000
– –
MTSR
41
DELISTED
Metsera Inc
MTSR
$1.36M 0.08%
+50,000
New +$1.42M
TCRX icon
42
TScan Therapeutics
TCRX
$50.6M
$915K 0.05%
662,833
-4,337,167
-87% -$9.38M
SRZNW icon
43
Surrozen Inc Warrant
SRZNW
$75.6K
$777K 0.05%
66,665
– –
ALGS icon
44
Aligos Therapeutics
ALGS
$26.3M
$731K 0.04%
88,569
-167,004
-65% -$3.66M
ETON icon
45
CALL
Eton Pharmaceutcials
ETON
$1.28B
$655K 0.04%
50,500
-100,900
-67% -$1.52M
UPB
46
Upstream Bio Inc
UPB
$348M
$367K 0.02%
60,000
– –
ARVN icon
47
Arvinas
ARVN
$529M
– –
-6,726,491
Closed -$129M
AVIR icon
48
Atea Pharmaceuticals
AVIR
$361M
– –
-3,341,653
Closed -$11.2M
CRGX
49
DELISTED
CARGO Therapeutics
CRGX
– –
-1,470,000
Closed -$21.2M
DSGN icon
50
Design Therapeutics
DSGN
$741M
– –
-426,683
Closed -$2.63M
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2025 Portfolio in Review

As of Q1 2025, EcoR1 Capital held 63 positions worth $1.69B, down 36% from $2.65B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

EcoR1 Capital withdrew a net $362M in Q1 2025, closing 17 positions and reducing 6 holdings. Its most notable exit was Arvinas, an estimated $129M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Akero Therapeutics worth $17.8M.

  • EcoR1 Capital's largest Q1 2025 buy was Akero Therapeutics: 440,000 shares worth $17.8M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2025, an estimated $55M increase.
  • EcoR1 Capital's biggest Q1 2025 reduction was TScan Therapeutics, cutting an estimated $9.38M.
  • EcoR1 Capital fully exited Arvinas in Q1 2025, selling an estimated $129M.
  • EcoR1 Capital's ten largest holdings make up 80% of its $1.69B portfolio in Q1 2025.
  • EcoR1 Capital opened 4 new positions and closed 17 in Q1 2025.
  • EcoR1 Capital's portfolio value fell 36% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.